Abstract:Background China’s pharmaceutical market is growing at a healthy pace. This is due to potential rising per capita income, an increasing elderly population, urbanisation demographics and more access to health care. Methodology The methodology used is a comparative study on the basis of original empirical research. More specifically, the part of examination facts and regulation has been written by conducting empirical research on current international and national resource concerning the subject from books, various guidelines, rules and regulation, articles, published reports and internet. Results Generally the regulatory environment in China has been considered as an very challenging one. From regulatory perspective, CFDA regulations have not been stringent enough nor has it been robust enough to create a quality supply of medications, with (1) concerns in the subject matter, quality comparison between international regulatory standard and usually accepted local products and manufactures set standards; (2) a timeline for regulatory assessment and authorization of new drugs which is much longer in comparison to most countries; (3) less number of regulatory reviewer which has led to a backlog of earlier application. The journey to reshape China from ‘made-in-China’ to ‘discovered-in-China’ is highly challenging. (4) Complications with local protection, corruption and a lack of transparency. The directives from Government has recognized the need for significant system-level transformations for streamlining the pharmaceutical regulatory environment. Conclusion Continuing on the route of reform is promising that all Chinese citizens is eventually having access to safe, effective and high-quality medications in affordable price. These reformations are encouraging and promising not only for China’s health care system, but also for global Pharmaceutical industry and that’s the reason, now many big Pharma companies are considering China as a prime focus. The companies need to make use of the new opportunities, accessible to experience the benefit of faster time-to-market, and cause rewarding growth prospect for both domestic/ multinational companies.

Discussion of Developing China as Clinical Research Center in Asian-Pacific Region

The problems and solutions concerning clinical medicine research in Healthy China 2020 program

Research report on guidance for the multi-regional clinical trials

A Development Opportunity and Strategic Thinking for the Comprehensive Healthcare Industry of Traditional Chinese Medicine

Focus on China: Should Clinicians Engage in Research? and Lessons from Other Countries.

The need for multicentre cardiovascular clinical trials in Asia

Thinking on clinical pharmacy in China

How to Strengthen Clinical Research in Shenzhen, China: Qualitative Study

Quality over Quantity: a Necessary Path for Clinical Research Transformation in China

Recent Advances in Drug Development and Regulatory Science in China

Current Status of Clinical Trials on Drugs and GCP in China

Challenges and prospects in Chinese pharmaceutical regulatory environment

An overview of innovative cancer drug clinical development in China

Guideline for [clinical Guidelines Constitution/Amendment] in China.

Encouraging an Environment for Pharmaceutical R&D in China

Reflection of Quality Management of Conducting International Cooperative Academic Clinical Research in China

The necessary conduct: Exploratory multiregional clinical trials in East Asia

Discussion on management of new drug clinical trials proj'ect

Development of Traditional Medicine in the Asia-Pacific Region

Barriers to the Introduction of Clinical Path in China at Present Situations

Analysis of clinical trials supported by foreign pharmaceutical industries in China